Cargando…
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
BACKGROUND: Although several COVID-19 vaccines have been developed so far, they will not be sufficient to meet the global demand. Development of a wider range of vaccines, with different mechanisms of action, could help control the spread of SARS-CoV-2 globally. We developed a protein subunit vaccin...
Autores principales: | Yang, Shilong, Li, Yan, Dai, Lianpan, Wang, Jianfeng, He, Peng, Li, Changgui, Fang, Xin, Wang, Chenfei, Zhao, Xiang, Huang, Enqi, Wu, Changwei, Zhong, Zaixin, Wang, Fengze, Duan, Xiaomin, Tian, Siyu, Wu, Lili, Liu, Yan, Luo, Yi, Chen, Zhihai, Li, Fangjun, Li, Junhua, Yu, Xian, Ren, Hong, Liu, Lihong, Meng, Shufang, Yan, Jinghua, Hu, Zhongyu, Gao, Lidong, Gao, George F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990482/ https://www.ncbi.nlm.nih.gov/pubmed/33773111 http://dx.doi.org/10.1016/S1473-3099(21)00127-4 |
Ejemplares similares
-
Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults
por: Dai, Lianpan, et al.
Publicado: (2022) -
A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates
por: An, Yaling, et al.
Publicado: (2022) -
Preclinical Toxicity and Immunogenicity of a COVID-19 Vaccine (ZF2001) in Cynomolgus Monkeys
por: Yang, Hongzhong, et al.
Publicado: (2022) -
Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3–17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial
por: Gao, Lidong, et al.
Publicado: (2023) -
Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants
por: Zhao, Xin, et al.
Publicado: (2021)